Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report
Current Oncology · 2025
DOI: 10.3390/curroncol32080469 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, 2025. Verfasst von Eugénie Roberge-Maltais und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Université Laval, Quebec City, QC G1V 0A6, Canada. Hauptthemen laut MEDLINE: Capillary Leak Syndrome, Antibodies, Monoclonal, Humanized, Cytokine Release Syndrome, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Systemic Capillary Leak Syndrome (SCLS) and Cytokine Release Syndrome (CRS) have both been described as rare but severe adverse reactions induced by Programmed cell death protein 1 (PD-1) inhibitors such as pembrolizumab. We report the case of a 40-year-old woman undergoing treatment with pembrolizumab for a stage 4 cervical squamous cell carcinoma who presented with anasarca, hypotension, hemoconcentration and signs of multisystemic inflammation. After elimination of alternative causes such as nephrotic syndrome, cardiac dysfunction and cirrhosis, she was diagnosed with both pembrolizumab-induced SCLS and CRS. She was successfully treated with a multimodal treatment approach including intravenous immunoglobulins, steroids, diuretics and axitinib for SCLS as well as ruxolitinib for CRS. After several months of hospitalization, her symptoms finally improved with this treatment regimen, and she was able to attain euvolemic state and be discharged from the hospital. This case highlights certain rare and severe adverse effects of treatment with PD-1 inhibitors. Furthermore, it proposes a novel therapeutic approach for similar cases based upon probable underlying physiopathological mechanisms in SCLS and CRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Université Laval, Quebec City, QC G1V 0A6, Canada.
- Department of Hemato-Oncology, CHU de Quebec, Université Laval, Quebec City, QC G1V 4G2, Canada.
- Department of Pharmacy, CHU de Quebec-Pavillon Hôtel-Dieu de Québec, Université Laval, Quebec City, QC G1R 2J6, Canada.
- Department of Internal Medicine, CHU de Quebec-Pavillon Hôtel-Dieu de Québec, Université Laval, Quebec City, QC G1R 2J6, Canada.
ORCID-Profile: Nicolas Marcoux, Louis-Philippe Grenier, Martin Veilleux
Zitieren
APA
Roberge-Maltais, E., Lévesque, E., Castonguay, V., Marcoux, N., Grenier, L. P., & Veilleux, M. (2025). Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report. Current Oncology. https://doi.org/10.3390/curroncol32080469
Vancouver
Roberge-Maltais E, Lévesque E, Castonguay V, Marcoux N, Grenier LP, Veilleux M. Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report. Current Oncology. 2025. doi:10.3390/curroncol32080469
BibTeX
@article{RobergeMaltais2025,
author = {Roberge-Maltais, Eugénie and Lévesque, Eric and Castonguay, Vincent and Marcoux, Nicolas and Grenier, Louis-Philippe and Veilleux, Martin},
title = {Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32080469}
}
EUVIMED